InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces $6.25M Registered Direct Offering
Processa Pharmaceuticals (NASDAQ: PCSA) is a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or quality of life. The company today announced its entry into definitive agreements with retail investors for the purchase and sale of 7,812,544 common shares, each at a price of $0.80, in a registered…